P3 Health Partners Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a Nasdaq Staff Delisting Determination received on September 28, 2022. The filing was signed on October 4, 2022. The company’s securities are listed on Nasdaq under the symbols PIII and PIIIW.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. The company stated that it was working with current and former auditors to complete a previously disclosed restatement and the audit of its financial statements for the year ended December 31, 2021.
Material Changes Versus the Prior Comparable Period
- Nasdaq initiated a process that could result in delisting because the company had not timely filed its Form 10-K for the year ended December 31, 2021, or its Forms 10-Q for the quarters ended March 31 and June 30, 2022.
- The company missed Nasdaq’s September 27, 2022 extension deadline for regaining compliance with Listing Rule 5250(c)(1), which requires timely SEC periodic filings.
- The Staff Determination did not immediately suspend trading or delist the company’s securities.
Guidance, Outlook, Risks, and Unusual Items
- The company expected to submit all delinquent periodic reports before or during the week of October 17, 2022, which it believed would restore compliance.
- The company intended to appeal the Staff Determination to a Nasdaq Hearing Panel by the October 5, 2022 deadline and seek a stay of any suspension or delisting action.
- A hearing request would automatically stay suspension for 15 days from the request date. The company also planned to request an additional stay pending the hearing process.
- There was no assurance that the delinquent reports would be filed before any hearing or that Nasdaq would grant a further stay.
- The company could pursue additional review by the Nasdaq Listing Council after a Hearing Panel decision.
Key Facts for Investors to Verify
- Whether the company filed the delinquent 2021 Form 10-K and 2022 first- and second-quarter Forms 10-Q by the stated target date.
- The results of the Nasdaq hearing, any stay, and the ultimate listing status of the company’s common stock and warrants.
- The scope and impact of the previously disclosed financial statement restatement.
- The audited 2021 financial results and any subsequent disclosures regarding liquidity, financing needs, or going-concern risks.